Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes
Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes
复制标题
KCNQ1多态性对中国2型糖尿病患者口服降糖药疗效的影响
DOI：
10.1038/clpt.2010.351
复制
发表时间：
2011-03-01
影响因子：
6.7
通讯作者：
Jia, W.
中科院分区：
文献类型：
--
作者：
Yu, W.;Hu, C.;Jia, W.
本研究的目的是探讨中国研究人群中KCNQ 1变异体对口服降糖药物反应的影响。一项为期48周的随机药物遗传学研究比较了瑞格列奈和罗格列酮在209例新诊断的2型糖尿病患者中的作用。在瑞格列奈队列中，rs 2237892 TT纯合子个体表现出较低的2小时血糖水平和显著较高的目标2小时血糖水平累积达标率（Plog-rank = 0.0383）高于C等位基因携带者;具有较多rs 2237892 C等位基因的患者在空腹胰岛素和胰岛素抵抗的稳态模型评估中均表现出较大的增加（此外，rs 2237895 C等位基因也与空腹胰岛素和HOMA-IR的更大增量相关（分别为P = 0.0274和0.0259）。相比之下，在罗格列酮队列中仅检测到rs 2237897与2小时血糖水平降低之间的相关性（P = 0.0321）。我们的研究结果表明，在中国2型糖尿病患者中，KCNQ 1多态性与瑞格列奈的疗效相关，也可能与罗格列酮的反应相关。
The aim of this study was to explore the impact of KCNQ1 variants on the responses to oral antidiabetic drugs in a Chinese study population. A 48-week randomized pharmacogenetics study compared the effects of repaglinide and rosiglitazone in 209 newly diagnosed patients with type 2 diabetes. In the repaglinide cohort, individuals who were rs2237892 TT homozygotes exhibited lower 2-h glucose levels and significantly higher cumulative attainment rates of target 2-h glucose levels (Plog-rank = 0.0383) than the C allele carriers; patients with a greater number of rs2237892 C alleles showed larger augmentations in both fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) (P = 0.0166 and 0.0026, respectively); moreover, the rs2237895 C allele was also associated with greater increments in both fasting insulin and HOMA-IR (P = 0.0274 and 0.0259, respectively). In contrast, only an association between rs2237897 and decrease in 2-h glucose levels was detected in the rosiglitazone cohort (P = 0.0321). Our results indicated that KCNQ1 polymorphisms are associated with repaglinide efficacy, and might also be associated with rosiglitazone response, in Chinese patients with type 2 diabetes.